OKYO Pharma Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OKYO Nasdaq 2836 okyopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for OKYO Pharma Limited

OKYO Pharma Limited's (NASDAQ:OKYO) Intrinsic Value Is Potentially 90% Above Its Share Price - Jan 6th, 2026 4:01 am
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer - Jan 5th, 2026 5:00 am
OKYO Pharma to Ring the Opening Bell at Nasdaq - Dec 19th, 2025 5:00 am
OKYO Pharma Announces Chairman and Founder Acquires Shares - Dec 15th, 2025 6:30 am
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain - Dec 11th, 2025 6:30 am
OKYO Pharma to Present at OIS XV in San Diego - Nov 18th, 2025 6:30 am
OKYO Pharma to Present at BIO-Europe 2025 in Vienna - Oct 29th, 2025 5:00 am
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain - Sep 22nd, 2025 6:30 am
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - Jul 17th, 2025 7:00 am
OKYO reports top-line data from neuropathic corneal pain therapy trial - Jul 17th, 2025 3:47 am
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - Jul 16th, 2025 7:21 am
OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders - Jun 14th, 2025 8:52 am
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited - Jun 11th, 2025 8:05 am
OKYO Pharma to Present at the Bio International Convention - Jun 11th, 2025 6:30 am
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit - May 19th, 2025 5:00 am
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain - May 1st, 2025 5:00 am
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - Apr 30th, 2025 5:00 am
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - Mar 31st, 2025 6:00 am
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain - Mar 10th, 2025 6:30 am
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod - Feb 12th, 2025 5:00 am